Search Results

Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration has accepted Eisai’s Supplemental Biologics License Application for monthly lecanemab-irmb intravenous maintenance dosing.

BioArctic received $100 million upfront with another $1.25 billion in potential milestone payments on the line for two pyroglutamate-amyloid-beta antibodies.

BioArctic AB announced that BioArctic AB and Eisai Co., Ltd., have entered into a research evaluation agreement regarding BAN2802, a potential new treatment combining BioArctic’s proprietary BrainTransporter™ technology with an undisclosed Alzheimer drug candidate.

Eisai Co., Ltd. and Biogen Inc. announced that Eisai submitted to the U.S. Food and Drug Administration a Supplemental Biologics License Application for monthly lecanemab-irmb intravenous maintenance dosing.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today the company will present the latest findings on lecanemab (U.S. brand name: LEQEMBI®), Eisai’s anti-amyloid beta (Aβ) protofibril* antibody for the treatment of Alzheimer’s disease (AD), at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™) from March 5-9 in Lisbon, Portugal, and virtually.

Due to Bristol Myers Squibb’s ongoing portfolio reprioritization, Eisai is taking over the development and commercialization of farletuzumab ecteribulin, an investigational antibody-drug conjugate targeting solid tumors.